Innovation

Researchers are looking for alternate possibilities for CRISPR, a technology that can edit a living organism's DNA, according to Gizmodo.

The FDA is ramping up its approvals of medications related to precision medicine treatment and diagnostics. To tap into this growing field of patient care, some hospitals and health systems are implementing their own precision medicine programs.

Anne Wojcicki, CEO and co-founder of direct-to-consumer genetic testing company 23andMe, spoke with Quartz reporter Leah Fessler about her career background and leadership approach during a Feb. 6 interview.

Editor's Note: This post originally appeared on Cardinal health's website. With the breakneck pace of change in healthcare, it’s getting harder to anticipate what’s next. Kristina Redgrave, an expert from Fuse by Cardinal Health, the company’s innovation center, shared her…

Paige.AI, a New York City-based computational pathology startup focused on cancer diagnosis and treatment and backed by $25 million in Series A funding, launched Feb. 5.

The majority of radiology leaders see potential in using machine learning capabilities to analyze breast imaging above other types of medical imaging, according to a Reaction Data survey.

Researchers are using artificial intelligence and machine learning to find better ways to protect people from this year's particularly aggressive flu season, according to NBC News.

A team of researchers from Philadelphia-based University of Pennsylvania expect to receive FDA clearance to conduct the first CRISPR trial treating human patients in the U.S., according to The Wall Street Journal.

The National Institutes of Health will launch a research program to encourage the development of genome-editing treatments for various diseases.

Since humans are able to detect subtle facial cues that may alert them to infections just hours before they take hold, artificial intelligence technologies may be able to work in a similar way, according to Smithsonian.com.